GenPlus

GenPlus is a specialty pharmaceutical company headquartered in Taiwan, dedicated to the development of innovative drug delivery systems. The company specializes in the 505(b)(2) regulatory pathway, focusing on transdermal patches and oral thin films to enhance the delivery of established molecules. Their primary therapeutic focus is on central nervous system (CNS) disorders, including Alzheimer's and Parkinson's diseases, as well as pain management. GenPlus maintains integrated capabilities for formulation research, clinical development, and GMP-compliant manufacturing. By improving patient compliance and reducing side effects, the company aims to provide significant clinical value in the global healthcare market.